Answers are grounded in this paper and cite their sources.
Analysis reveals updated prevalence of obesity in the US, indicating preclinical cases eligible for prevention require distinct consideration.
Using the Commission's added measures yields refined population estimates for two categories-preclinical and clinical obesity. These updated estimates separate preclinical cases-at elevated risk and eligible for prevention-from those meeting clinical-obesity criteria, who require intervention.
No takes yet. Share an insight, caveat, or question.
Kranjac et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: